论文部分内容阅读
目的观察依达拉奉联合奥扎格雷钠治疗缺血性脑卒中的临床疗效,探讨其对血清炎性因子水平和血液流变学的影响。方法选取2012年5月—2016年3月重庆市荣昌区人民医院收治的缺血性脑卒中患者70例,根据治疗方案分为对照组和观察组,每组35例。在常规治疗基础上,对照组患者给予依达拉奉治疗,观察组患者给予依达拉奉联合奥扎格雷钠治疗;两组患者均连续治疗10 d。比较两组患者临床疗效及治疗前后血清炎性因子[超敏C反应蛋白(hs-CRP)、白介素6(IL-6)及肿瘤坏死因子α(TNF-α)]水平、血液流变学指标[全血高切黏度、全血低切黏度、血细胞比容(HCT)及血小板聚集率]。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前两组患者血清hs-CRP、IL-6及TNF-α水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血清hs-CRP、IL-6及TNF-α水平均低于对照组(P<0.05)。治疗前两组患者全血高切黏度、低切黏度、HCT及血小板聚集率比较,差异无统计学意义(P>0.05);治疗后观察组患者全血高切黏度、低切黏度、HCT及血小板聚集率均低于对照组(P<0.05)。结论依达拉奉联合奥扎格雷钠治疗缺血性脑卒中的临床疗效确切,可有效减轻炎性反应,改善血液流变学。
Objective To observe the clinical efficacy of edaravone and ozagrel sodium in the treatment of ischemic stroke, and to explore its effect on serum inflammatory cytokines and hemorheology. Methods Seventy patients with ischemic stroke admitted to Rongchang District People’s Hospital of Chongqing from May 2012 to March 2016 were selected and divided into control group and observation group with 35 cases in each group. On the basis of routine treatment, patients in the control group were treated with edaravone, and patients in the observation group were treated with edaravone and ozagrel sodium. Patients in both groups were treated continuously for 10 days. The clinical efficacy and serum levels of inflammatory cytokines (hs-CRP, IL-6 and TNF-α) in both groups were compared before and after treatment, [Whole blood high shear viscosity, whole blood low shear viscosity, hematocrit (HCT), and platelet aggregation rate]. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). There was no significant difference in serum hs-CRP, IL-6 and TNF-α levels between the two groups before treatment (P> 0.05). After treatment, the levels of hs-CRP, IL-6 and TNF- Lower than the control group (P <0.05). There was no significant difference between the two groups before and after treatment in terms of high shear viscosity, low shear viscosity, HCT and platelet aggregation rate (P> 0.05). After treatment, whole blood high shear viscosity, low shear viscosity, Platelet aggregation rate was lower than the control group (P <0.05). Conclusion Edaravone combined with ozagrel sodium in the treatment of ischemic stroke clinical efficacy is exact, can effectively reduce the inflammatory response and improve hemorheology.